Aldehyde Dehydrogenase (ALDH) Inhibitor

Citral (Standard) is the analytical standard of Citral. This product is intended for research and analytical applications. Citral is an orally active monoterpene compound in lemon grass essential oil and a natural ALDH1A inhibitor, which can induce apoptosis and cycle arrest in breast cancer cell lines, and has analgesic, anti-injurious and anti-inflammatory effects.

Aldh2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Aldh2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABD-3001 is an inhibitor of ALDH1. ABD-3001 can be studied in research on refractory/relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

IGUANA-1 free base (STL5-T-0057) is an selective ALDH1 B1 inhibitor with an IC₅₀ value of 30 nM. IGUANA-1 free base inhibits cell growth of SW480 cells in adherent and spheroid conditions with IC₅₀ values of 2.46 and 0.39 μM, respectively. IGUANA-1 free base can be used for the research of cancer.

RV01 is an analogue of resveratrol, inhibits DNA damage, reduces acetaldehyde dehydrogenase 2 (ALDH2) mRNA expression induced by ethanol, and exhibits hydroxyl radical scavenging activity. RV01 decreases iNOS expression, with anti-neuroinflammatory activity.

CM026 is a selective aldehyde dehydrogenase 1A1 inhibitor with submicromolar inhibitory activity against aldehyde dehydrogenase 1A1. Its inhibitory mechanism is related to binding to the aldehyde binding pocket and utilizing a unique glycine residue. It can be used as a chemical tool to study the role of this enzyme in disease.

7-Hydroxy-4-phenylcoumarin is a dual ALDH-2 and MAO inhibitor, with IC₅₀ values of 1.5 and 0.5 µM, respectively.

FSI-TN42 (N42) is a selective, orally active and irreversible ALDH1A1 inhibitor with an IC₅₀ of 23 nM. FSI-TN42 shows 800-fold more potent against ALDH1A1 than ALDH1A2 (IC₅₀obesity.

ALDH2 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CM121 is an active site-directed reversible ALDH1A2 inhibitor (IC₅₀=0.54 μM；Kd=1.1 μM) with a variety of hydrophobic interactions.

Taraxerone is isolated from Sedum sarmentosum. Taraxerone enhances effects on alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) activities with EC₅₀ values of 512.42 and 500.16 μM, respectively.

ALDH3A1-IN-4 is a selective ALDH3A1 inhibitor with an IC₅₀ of 0.2 μM. ALDH3A1-IN-4 binds to the aldehyde-binding pocket of ALDH3A1 via hydrophobic interactions and van der Waals forces. ALDH3A1-IN-4 acts as a chemosensitizer that sensitizes ALDH3A1-expressing cancer cells to the antiproliferative effect of mafosfamide, but does not produce a sensitizing effect on non-cancer cells that do not express ALDH3A1. ALDH3A1-IN-4 is applicable to research related to lung adenocarcinoma and glioblastoma.

Coprine is an orally active disulfiram (HY-B0240)-like component and an inhibitor of aldehyde dehydrogenase. Coprine is isolated from Coprinus atranentarius. Coprine inhibits low K_m aldehyde dehydrogenase in rat liver and increases blood acetaldehyde levels during in vivo ethanol metabolism. Coprine does not inhibit semi-purified low K_m aldehyde dehydrogenase from rat liver in vitro. Coprine can be used in studies related to alcoholism.

4-Hydroxynonenal (Standard) is the analytical standard of 4-Hydroxynonenal. This product is intended for research and analytical applications. 4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of acetaldehyde dehydrogenase 2 (ALDH2). 4-Hydroxynonenal can modulate a number of signaling processes mainly through forming covalent adducts with nucleophilic functional groups in proteins, nucleic acids, and membrane lipids. 4-Hydroxynonenal plays an important role in cancer through mitochondria.

KS124 (compound 3) is a potent ALDH inhibitor. KS124 shows inhibition for ALDH1A1, ALDH1A3, ALDH3A1. KS124 shows antiproliferative activity. KS124 induces apoptosis and ROS production.

Neuroprotective agent 15 (Compound 3e) is a neuroprotective agent. Neuroprotective agent 15 is a selective butyrylcholinesterase (BChE) inhibitor, with IC₅₀ values of 2.6 and 114.3 μM for BChE and AChE respectively. Neuroprotective agent 15 has cannabinoid CB2 receptor (CB2 receptor) agonistic activity. Neuroprotective agent 15 can reduce cell death, LDH release and Caspase-3/7 activity, and inhibit apoptosis. Neuroprotective agent 15 can reduce the formation of superoxide free radicals, maintain cell morphology, and significantly lower oxidative stress levels. Neuroprotective agent 15 can be used in the research of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Dyclonine (Dyclocaine) is an orally active, blood-brain barrier-permeable piperidine phenylacetone small molecule commonly used as a local anesthetic. Dyclonine acts as a highly selective allosteric antagonist of TRPV3; it also reversibly inhibits G9a, ALDH2 and ALDH3A1, non-competitively blocks AChE. Dyclonine activates the Nrf2/ARE pathway, relieves the epigenetic silencing of FXN, blocks Aβ42 aggregation, and promotes remyelination and reparative polarization of microglia. Dyclonine alleviates pruritus via TRPV3 inhibition; it is used in studies of neurodegenerative disease models based on its AChE inhibitory, antioxidant and remyelinating effects; it sensitizes drug-resistant tumors through ALDH inhibition, and combined use with protease inhibitors induces more tumor cell apoptosis; it inhibits Candida albicans in vitro. Dyclonine can be used for research on multiple diseases including neurodegenerative diseases, cancer and pruritic dermatitis.

Dyclonine-d₉ hydrochloride (Dyclocaine-d₉ hydrochloride) is the deuterated-labeled Dyclonine hydrochloride (HY-B0364A). Dyclonine hydrochloride (Dyclocaine hydrochloride) is an orally active, blood-brain barrier-permeable piperidine phenylacetone small molecule commonly used as a local anesthetic. Dyclonine hydrochloride acts as a highly selective allosteric antagonist of TRPV3; it also reversibly inhibits G9a, ALDH2 and ALDH3A1, non-competitively blocks AChE. Dyclonine hydrochloride activates the Nrf2/ARE pathway, relieves the epigenetic silencing of FXN, blocks Aβ42 aggregation, and promotes remyelination and reparative polarization of microglia. Dyclonine hydrochloride alleviates pruritus via TRPV3 inhibition; it is used in studies of neurodegenerative disease models based on its AChE inhibitory, antioxidant and remyelinating effects; it sensitizes drug-resistant tumors through ALDH inhibition, and combined use with protease inhibitors induces more tumor cell apoptosis; it inhibits Candida albicans in vitro. Dyclonine hydrochloride can be used for research on multiple diseases including neurodegenerative diseases, cancer and pruritic dermatitis.

Lefelsiran sodium is a siRNA targeted to ALDH2. It is used for the study of alcohol use disorder.

Aurora kinase/ALK-IN-1 is a dual Aurora A kinase and ALK inhibitor with IC₅₀ values of 0.296 μM and 0.332 μM, respectively. Aurora kinase/ALK-IN-1 induces G₂/M cell cycle arrest, triggers mitochondrial apoptosis, elevates intracellular reactive oxygen species (ROS) levels, and inhibits ALDH1 activity. Aurora kinase/ALK-IN-1 demonstrates cytotoxicity and tumor selectivity. Aurora kinase/ALK-IN-1 can be used for the research of anaplastic large cell lymphoma.